Determining the time course of CYP3A inhibition by potent reversible and irreversible CYP3A inhibitors using A...

Area of Science:

• Pharmacology
• Drug Metabolism
• Clinical Trials

Background:

• Cytochrome P450 3A (CYP3A) is a key enzyme in drug metabolism.
• Understanding CYP3A inhibition kinetics is crucial for safe drug combinations.
• Voriconazole and ritonavir are known CYP3A inhibitors with different mechanisms.

Purpose of the Study:

• To establish and validate a limited sampling strategy for assessing CYP3A activity.
• To evaluate the time course of reversible (voriconazole) and irreversible (ritonavir) CYP3A inhibition.
• To correlate plasma midazolam (MDZ) area under the curve (AUC) with MDZ clearance.

Main Methods:

• A randomized trial involving 16 healthy participants (2 groups of 8).
• Administration of oral voriconazole or ritonavir for 9 days.
• Timed oral administration of midazolam (MDZ) at multiple time points relative to inhibitor treatment.

Main Results:

• Plasma MDZ AUC (2-4h) strongly correlated with MDZ clearance, validating the limited sampling strategy.
• Maximum CYP3A inhibition by both voriconazole and ritonavir occurred within 48 hours.
• Voriconazole inhibition showed a 24-hour recovery half-life, while ritonavir inhibition persisted 3 days post-discontinuation.

Conclusions:

• The limited sampling strategy is effective for assessing CYP3A inhibition.
• Early and gradual alterations in CYP3A activity occur during and after inhibitor therapy.
• Findings highlight the need for careful dose adjustments in combination therapies involving CYP3A inhibitors.